A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease | Zendy

Matthew R. Weir | Zendy; Pablo E. Pérgola | Zendy; Rajiv Agarwal | Zendy; Jeffrey C. Fink | Zendy; Nelson Kopyt | Zendy; Ajay Singh | Zendy; Kumar Jayant | Zendy; Susanne Schmitt | Zendy; Gregor Schaffar | Zendy; Anita Rudy | Zendy; Jim P. McKay | Zendy; Radmila Kančeva | Zendy

Open Access

A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease

Author(s) -

Matthew R. Weir,

Pablo E. Pérgola,

Rajiv Agarwal,

Jeffrey C. Fink,

Nelson Kopyt,

Ajay Singh,

Kumar Jayant,

Susanne Schmitt,

Gregor Schaffar,

Anita Rudy,

Jim P. McKay,

Radmila Kančeva

Publication year - 2017

Publication title -

american journal of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.394

H-Index - 85

eISSN - 1421-9670

pISSN - 0250-8095

DOI - 10.1159/000481736

Subject(s) - medicine , epoetin alfa , anemia , kidney disease , peritoneal dialysis , hemodialysis , erythropoietin , gastroenterology , clinical endpoint , dialysis , urology , clinical trial , surgery

HX575 (biosimilar epoetin alfa) was approved in Europe in 2007 for the treatment of chronic kidney disease (CKD)-related anemia. This study assessed the clinical equivalence of HX575 with the US-licensed reference epoetin alfa (Epogen®/Procrit®, Amgen/Janssen) following subcutaneous (SC) administration in dialysis patients with CKD-related anemia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research